Aclaris Net Debt vs Property Plant Equipment Analysis
ACRS Stock | USD 1.20 0.01 0.84% |
Aclaris Therapeutics financial indicator trend analysis is way more than just evaluating Aclaris Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aclaris Therapeutics is a good investment. Please check the relationship between Aclaris Therapeutics Net Debt and its Property Plant Equipment accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.
Net Debt vs Property Plant Equipment
Net Debt vs Property Plant Equipment Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aclaris Therapeutics Net Debt account and Property Plant Equipment. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Aclaris Therapeutics' Net Debt and Property Plant Equipment is -0.26. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Property Plant Equipment in the same time period over historical financial statements of Aclaris Therapeutics, assuming nothing else is changed. The correlation between historical values of Aclaris Therapeutics' Net Debt and Property Plant Equipment is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Aclaris Therapeutics are associated (or correlated) with its Property Plant Equipment. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant Equipment has no effect on the direction of Net Debt i.e., Aclaris Therapeutics' Net Debt and Property Plant Equipment go up and down completely randomly.
Correlation Coefficient | -0.26 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Property Plant Equipment
Most indicators from Aclaris Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aclaris Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.Discontinued Operations is likely to gain to about 167.8 K in 2024, whereas Selling General Administrative is likely to drop slightly above 21.3 M in 2024.
Aclaris Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Aclaris Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aclaris Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 98.3M | 70.8M | 251.2M | 254.6M | 197.4M | 169.3M | |
Other Current Liab | 12.0M | 4.2M | 3.1M | 2.2M | 10.9M | 4.4M | |
Total Current Liabilities | 22.4M | 14.9M | 22.9M | 21.9M | 31.0M | 16.3M | |
Total Stockholder Equity | 69.9M | 37.7M | 197.3M | 197.6M | 157.2M | 133.2M | |
Other Liab | 2.4M | 7.6M | 28.8M | 33.5M | 38.5M | 40.4M | |
Property Plant And Equipment Net | 2.5M | 1.7M | 1.3M | 1.1M | 1.6M | 1.6M | |
Net Debt | (35.3M) | (42.9M) | (26.7M) | (44.6M) | (39.5M) | (41.4M) | |
Retained Earnings | (453.5M) | (504.5M) | (595.4M) | (682.3M) | (770.8M) | (732.3M) | |
Accounts Payable | 9.9M | 5.3M | 10.0M | 10.4M | 8.9M | 7.2M | |
Cash | 35.9M | 54.1M | 27.3M | 45.3M | 39.9M | 52.9M | |
Non Current Assets Total | 14.5M | 13.3M | 46.2M | 23.0M | 68.5M | 72.0M | |
Cash And Short Term Investments | 75.0M | 54.1M | 225.7M | 229.8M | 119.1M | 137.6M | |
Common Stock Shares Outstanding | 41.3M | 42.5M | 56.7M | 65.2M | 69.8M | 38.5M | |
Short Term Investments | 39.1M | 32.1M | 164.1M | 172.3M | 79.2M | 96.3M | |
Liabilities And Stockholders Equity | 98.3M | 70.8M | 251.2M | 254.6M | 197.4M | 169.3M | |
Non Current Liabilities Total | 6.0M | 18.3M | 30.9M | 35.0M | 9.3M | 8.8M | |
Other Current Assets | 3.1M | 2.6M | 13.0M | 13.5M | 9.5M | 5.7M | |
Other Stockholder Equity | 523.5M | 542.3M | 793.0M | 880.8M | 928.1M | 495.6M | |
Total Liab | 28.4M | 33.1M | 53.9M | 57.0M | 40.2M | 36.1M | |
Property Plant And Equipment Gross | 2.5M | 1.7M | 4.7M | 5.1M | 5.8M | 6.1M | |
Total Current Assets | 83.8M | 57.5M | 205.0M | 231.6M | 128.9M | 139.1M | |
Accumulated Other Comprehensive Income | (66K) | (94K) | (224K) | (897K) | (106K) | (111.3K) | |
Property Plant Equipment | 7.2M | 1.7M | 1.3M | 1.1M | 1.3M | 1.9M | |
Net Tangible Assets | 62.7M | 30.5M | 190.3M | 190.6M | 219.2M | 135.0M | |
Non Currrent Assets Other | 4.8M | 4.5M | 3.6M | (630K) | 1.7M | 1.8M | |
Other Assets | 92K | 4.5M | 251.2M | 1.7M | 2.0M | 1.9M | |
Net Receivables | 704K | 772K | 623K | 484K | 298K | 283.1K | |
Retained Earnings Total Equity | (453.5M) | (504.5M) | (595.4M) | (682.3M) | (614.1M) | (583.4M) | |
Capital Surpluse | 523.5M | 542.3M | 793.0M | 880.8M | 1.0B | 553.9M | |
Inventory | 791K | 5.0M | (34.2M) | (12.2M) | (11.0M) | (10.5M) | |
Intangible Assets | 7.2M | 7.1M | 7.0M | 7.0M | 269K | 255.6K | |
Non Current Liabilities Other | 5.4M | 7.2M | 30.6M | 34.7M | 9.3M | 13.1M | |
Short Long Term Debt Total | 637K | 11.3M | 693K | 684K | 426K | 404.7K | |
Capital Lease Obligations | 637K | 603K | 693K | 684K | 426K | 594.9K | |
Net Invested Capital | 69.9M | 48.3M | 197.3M | 197.6M | 157.2M | 130.4M | |
Net Working Capital | 61.4M | 42.6M | 182.1M | 209.6M | 97.9M | 106.7M |
Pair Trading with Aclaris Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aclaris Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aclaris Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Aclaris Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aclaris Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aclaris Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aclaris Therapeutics to buy it.
The correlation of Aclaris Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aclaris Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aclaris Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aclaris Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Aclaris Stock analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Aclaris Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aclaris Therapeutics. If investors know Aclaris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aclaris Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Revenue Per Share 0.448 | Quarterly Revenue Growth 1.266 | Return On Assets (0.33) | Return On Equity (0.50) |
The market value of Aclaris Therapeutics is measured differently than its book value, which is the value of Aclaris that is recorded on the company's balance sheet. Investors also form their own opinion of Aclaris Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aclaris Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aclaris Therapeutics' market value can be influenced by many factors that don't directly affect Aclaris Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aclaris Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aclaris Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aclaris Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.